| (1) |
Figge J. Epidemiology of thyroid cancer. In: Wartofsky
L, ed. Thyroid Cancer: a comprehensive guide to clinical management. Totowa:
Humana Press, 1999; 77-83. |
| (2) |
Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic
factors for thyroid carcinoma: A population-based study of 15,698 cases
from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991.
Cancer 1997; 79: 564-73. |
| (3) |
Teppo L, Hakulinen T. Eurocare Working Group. Variation
in survival of adult patients with thyroid cancer in Europe. Eur J Cancer
1998; 34: 2248-52. |
| (4) |
Maldonado MR, Sherman SI. Predictive value of clinicopathologic
staging for medullary thyroid carcinoma. 72nd Annual Meeting of the American
Thyroid Association; 1999; Palm Beach, FL, 1999. |
| (5) |
Dinneen SF, Valimaki MJ, Bergstralh EJ, et al. Distant
metastases in papillary thyroid carcinoma: 100 cases observed at one institution
during 5 decades. J Clin Endocrinol Metab 1995; 80: 2041-5. |
| (6) |
Kumar H, Daykin J, Holder R, et al. An audit of management of differentiated
thyroid cancer in specialist and non-specialist clinic settings. Clin Endocrinol
(Oxf) 2001; 54 (6): 719-23. |
| (7) |
British Thyroid Association and Royal College of Physicians.
Guidelines for the management of thyroid cancer in adults London: Guidelines
for the management of thyroid cancer in adults, 2002. |
| (8) |
Task Force TC. AACE/AAES medical/surgical guidelines for clinical practice:
Management of thyroid carcinoma. Endocr Pr 2001; 7: 203-20. |
| (9) |
Sherman SI. NCCN practice guidelines for thyroid cancer,
version 2001. National Comprehensive Cancer Network, 2001. |
| (10) |
Brandi ML, Gagel RF, Angeli A, et al. Jr., Marx SJ. Guidelines for diagnosis
and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86:
5658-71. |
| (11) |
Singer PA, Cooper DS, Daniels GH, et al. Treatment guidelines
for patients with thyroid nodules and well-differentiated thyroid cancer.
Arch Intern Med 1996; 156: 2165-72. |
| (12) |
Ravetto C, Colombo L, Dottorini ME. Usefulness of fine-needle
aspiration in the diagnosis of thyroid carcinoma: a retrospective study
in 37,895 patients. Cancer 2000; 90: 357-63. |
| (13) |
Gharib H, Goellner JR. Fine-needle aspiration biopsy
of the thyroid: an appraisal. Ann Intern Med 1993; 118 (4): 282-89. |
| (14) |
Baloch ZW, Fleisher S, LiVolsi VA, Gupta PK. Diagnosis
of "follicular neoplasm": a gray zone in thyroid fine-needle aspiration
cytology. Diagn Cytopathol 2002; 26: 41-44. |
| (15) |
Tyler DS, Winchester DJ, Caraway NP, Hickey RC, Evans
DB. Indeterminate fine-needle aspiration biopsy of the thyroid. Identification
of subgroups at high risk for invasive carcinoma. Surgery 1994; 116 (12):
1054-60. |
| (16) |
Tuttle RM, Lemar H, Burch HB. Clinical features associated with an increased
risk of thyroid malignancy in patients with follicular neoplasia by fine-needle
aspiration. Thyroid 1998; 8: 377-83. |
| (17) |
Bartolazzi A, Gasbarri A, Papotti M, et al. Application
of an immunodiagnostic method for improving preoperative diagnosis of nodular
thyroid lesions. Lancet 2001; 357: 1644-50. |
| (18) |
Udelsman R, Westra WH, Donovan PI, Sohn TA, Cameron JL. Randomized prospective
evaluation of frozen-section analysis for follicular neoplasms of the thyroid.
Ann Surg 2001; 23: 716-22. |
| (19) |
Roach JC, Heller KS, Dubner S, Sznyter LA. The value
of frozen section examinations in determining the extent of thyroid surgery
in patients with indeterminate fine-needle aspiration cytology. Arch Otolaryngol
Head Neck Surg 2002; 128: 263-67. |
| (20) |
Cramer H. Fine-needle aspiration cytology of the thyroid: an appraisal.
Cancer 2000; 90: 325-29. |
| (21) |
Cases JA, Surks MI. The changing role of scintigraphy
in the evaluation of thyroid nodules. Semin Nucl Med 2000; 30: 81-87. |
| (22) |
Ezzat S, Sarti DA, Cain DR, Braunstein GD. Thyroid incidentalomas. Prevalence
by palpation and ultrasonography. Arch Intern Med 1994; 154: 1838-40. |
| (23) |
Burguera B, Gharib H. Thyroid incidentalomas. Prevalence,
diagnosis, significance, and management. Endocrinol Metab Clin North Am
2000; 29: 187-203. |
| (24) |
Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable
nodules discovered incidentally on thyroid imaging. Ann Intern Med 1997;
126: 226-31. |
| (25) |
Figge J, Jennings T, Gerasimov G. Radiation and thyroid
cancer. In: Wartofsky L, ed. Thyroid cancer: a comprehensive guide to clinical
management. Totowa: Humana Press, 1999: 85-116. |
| (26) |
Pacini F, Vorontsova T, Demidchik EP, et al. Post-Chernobyl thyroid carcinoma
in Belarus children and adolescents: comparison with naturally occurring
thyroid carcinoma in Italy and France. J Clin Endocrinol Metab 1997; 82:
3563-69. |
| (27) |
Musholt TJ, Musholt PB, Petrich T, et al. Familial papillary
thyroid carcinoma: genetics, criteria for diagnosis, clinical features,
and surgical treatment. World J Surg 2000; 24: 1409-17. |
| (28) |
Alsanea O, Wada N, Ain K, et al. Is familial non-medullary thyroid carcinoma
more aggressive than sporadic thyroid cancer? A multicenter series. Surgery
2000; 128: 1043-50. |
| (29) |
McKay JD, Lesueur F, Jonard L, et al. Localization of
a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome
2q21. Am J Hum Genet 2001; 69: 440-46. |
| (30) |
Fagin JA. Molecular pathogenesis of tumors of thyroid follicular cells.
In: Fagin JA, ed. Thyroid Cancer. Boston: Kluwer, 1998. |
| (31) |
Nikiforova MN, Stringer JR, Blough R, et al. Proximity
of chromosomal loci that participate in radiation-induced rearrangements
in human cells. Science 2000; 290: 138-41. |
| (32) |
Elisei R, Shiohara M, Koeffler HP, Fagin JA. Genetic and epigenetic alterations
of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human
thyroid carcinoma cell lines and primary thyroid carcinomas. Cancer 1998;
83: 2185-93. |
| (33) |
Ouyang B, Knauf JA, Ain K, Nacev B, Fagin JA. Mechanisms
of aneuploidy in thyroid cancer cell lines and tissues: evidence for mitotic
checkpoint dysfunction without mutations in BUB1 and BUBR1. Clin Endocrinol
(Oxf) 2002; 56: 341-50. |
| (34) |
Specht MC, Barden CB, Fahey TJ 3rd. p44/p42-MAP kinase expression in papillary
thyroid carcinomas. Surgery 2001; 130: 936-40. |
| (35) |
Saavedra HI, Knauf JA, Shirokawa JM, et al. The RAS
oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK
pathway. Oncogene 2000; 19: 3948-54. |
| (36) |
Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARgamma1 fusion oncogene
in human thyroid carcinoma [corrected]. Science 2000; 289: 1357-60. |
| (37) |
Minireview FJA. branded from the start-distinct oncogenic
initiating events may determine tumor fate in the thyroid. Mol Endocrinol
2002; 16: 903-11. |
| (38) |
Byar DP, Green SB, Dor P, et al. A prognostic index for thyroid carcinoma.
A study of the E O R T C thyroid cancer cooperative group. Eur J Cancer
1979; 15: 1033-41. |
| (39) |
Cady B, Rossi R. An expanded view of risk-group definition
in differentiated thyroid carcinoma. Surgery 1988; 104: 947-53. |
| (40) |
Hermanek P, Sobin LH. TNM Classification of Malignant Tumours. 4th edn,
2nd rev edn. Berlin: Springer, 1992. |
| (41) |
Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral
lobectomy versus bilateral lobar resection in papillary thyroid carcinoma:
a retrospective analysis of surgical outcome using a novel prognostic scoring
system. Surgery 1987; 102: 1088-95. |
| (42) |
Hay ID, Bergstralh EJ, Goellner J, Ebersold JR, Grant CS. Predicting outcome
in papillary carcinoma: Development of a reliable prognostic scoring system
in a cohort of 1779 patients treated surgically at one institution during
1940 through 1989. Surgery 1993; 114: 1050-58. |
| (43) |
DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural
history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol
Metab 1990; 71: 414-24. |
| (44) |
Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical
therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418-28. |
| (45) |
Sherman SI, Brierley JD, Sperling M, et al. HR. Prospective
multicenter study of treatment of thyroid carcinoma: initial analysis of
staging and outcome. Cancer 1998; 83: 1012-21. |
| (46) |
Brierley JD, Panzarella T, Tsang RW, Gospodarowicz MK, O'Sullivan B. A
comparison of different staging systems predictability of patient outcome.
Thyroid carcinoma as an example. Cancer 1997; 79: 2414-23. |
| (47) |
Sherman SI. Toward a standard clinicopathologic staging
approach for differentiated thyroid carcinoma. Semin Surg Oncol 1999; 16
(1): 12-15. |
| (48) |
Association of Directors of Anatomic and Surgical Pathology. Recommended
reporting format for thyroid carcinoma. Am J Clin Pathol 2000; 11 (5): 684-86. |
| (49) |
Burman KD, Ringel MD, Wartofsky L. Unusual types of
thyroid neoplasms. Endocrinol Metab Clin North Am 1996; 25: 49-68. |
| (50) |
Katoh R, Sasaki J, Kurihara H, et al. Multiple thyroid involvement (intraglandular
metastasis) in papillary thyroid carcinoma. A clinicopathologic study of
105 consecutive patients. Cancer 1992; 70: 1585-90. |
| (51) |
Silverberg SG, Hutter RVP, Foote FW Jr. Fatal carcinoma
of the thyroid: histology, metastases, and causes of death. Cancer 1970;
25: 792-802. |
| (52) |
Hay ID, Grant CS, Bergstralh EJ, Thompson GB, van Heerden JA, Goellner
JR. Unilateral total lobectomy: is it sufficient surgical treatment for
patients with AMES low-risk papillary thyroid carcinoma? Surgery 1998; 124:
958-66. |
| (53) |
Taylor T, Specker B, Robbins J, et al. Outcome after
treatment of high-risk papillary and non-Hurthle-cell follicular thyroid
carcinoma. Ann Intern Med 1998; 129: 622-27. |
| (54) |
DeGroot LJ, Kaplan EL, Straus FH. Does the method of management of papillary
thyroid carcinoma make a difference in outcome? World J Surg 1994; 18: 123-30. |
| (55) |
Samaan NA, Schultz PN, Hickey RC, et al. The results
of various modalities of treatment of well differentiated thyroid carcinoma:
a retrospective review of 1599 patients. J Clin Endocrinol Metab 1992; 75:
714-20. |
| (56) |
Cady B. Papillary carcinoma of the thyroid gland: treatment based on risk
group definition. Surg Oncol Clin N Am 1998; 7: 633-44. |
| (57) |
Shaha AR, Shah JP, Loree TR. Low-risk differentiated
thyroid cancer: the need for selective treatment. Ann Surg Oncol 1997; 4:
328-33. |
| (58) |
Sherman SI. The risks of thyroidectomy: words of caution for referring
physicians. J Gen Intern Med 1998; 13: 60-61. |
| (59) |
Grant CS. Operative and postoperative management of
the patient with follicular and Hurthle cell carcinoma. Surg Clin N Am 1995;
75: 395-403. |
| (60) |
Grebe SK, Hay ID. Thyroid cancer nodal metastases: biologic significance
and therapeutic considerations. Surg Oncol Clin N Am 1996; 5: 43-63. |
| (61) |
Vassilopoulou-Sellin R, Schultz PN, Haynie TP. Clinical
outcome of patients with papillary thyroid carcinoma who have recurrence
after initial radioactive iodine therapy. Cancer 1996; 78: 493-501. |
| (62) |
Simon D, Goretzki PE, Witte J, Roher HD. Incidence of regional recurrence
guiding radicality in differentiated thyroid carcinoma. World J Surg 1996;
20: 860-66. |
| (63) |
Gillenwater AM, Goepfert H. Surgical management of laryngotracheal
and esophageal involvement by locally advanced thyroid cancer. Semin Surg
Oncol 1999; 16: 19-29. |
| (64) |
Catz B, Petit D, Schwartz M, Davis F, McCammon C, Starr P. Treatment of
cancer of the thyroid postoperatively with suppressive thyroid medication,
radioiodine, and thyroid-stimulating hormone. Cancer 1959; 12: 371-83. |
| (65) |
Maxon HR, Thomas SR, Samaratunga RC. Dosimetric considerations
in the radioiodine treatment of macrometastases and micrometastases from
differentiated thyroid cancer. Thyroid 1997; 7: 183-88. |
| (66) |
Wong JB, Kaplan MM, Meyer KB, Pauker SG. Ablative radioactive iodine therapy
for apparently localized thyroid carcinoma: a decision analytic perspective.
Endocrinol Metab Clin North Am 1990; 19: 741-60. |
| (67) |
Schlumberger M, Tubiana M, De Vathaire F, et al. Long-term
results of treatment of 283 patients with lung and bone metastases from
differentiated thyroid carcinoma. J Clin Endocrinol Metab 1986; 63: 960-67. |
| (68) |
Goldman JM, Line BR, Aamodt RL, Robbins J. Influence of triiodothyronine
withdrawal time on 131I uptake post-thyroidectomy for thyroid cancer. J
Clin Endocrinol Metab 1980; 50: 734-39. |
| (69) |
Lakshmanan M, Schaffer A, Robbins J, Reynolds J, Norton
J. A simplified low iodine diet in I-131 scanning and therapy of thyroid
cancer. Clin Nucl Med 1988; 13: 866-68. |
| (70) |
Sherman SI, Tielens ET, Sostre S, Wharam MD Jr, Ladenson PW. Clinical
utility of posttreatment radioiodine scans in the management of patients
with thyroid carcinoma. J Clin Endocrinol Metab 1994; 78: 629-34. |
| (71) |
Muratet JP, Daver A, Minier JF, Larra F. Influence of
scanning doses of iodine-131 on subsequent first ablative treatment outcome
in patients operated on for differentiated thyroid carcinoma. J Nucl Med
1998; 39: 1546-50. |
| (72) |
Mandel SJ, Shankar LK, Benard F, Yamamoto A, Alavi A. Superiority of iodine-123
compared with iodine-131 scanning for thyroid remnants in patients with
differentiated thyroid cancer. Clin Nucl Med 2001; 26: 6-9. |
| (73) |
Logue JP, Tsang RW, Brierley JD, Simpson WJ. Radioiodine
ablation of residual tissue in thyroid cancer: relationship between administered
activity, neck uptake and outcome. Br J Radiol 1994; 67: 1127-31. |
| (74) |
Bal C, Padhy AK, Jana S, Pant GS, Basu AK. Prospective randomized clinical
trial to evaluate the optimal dose of 131 I for remnant ablation in patients
with differentiated thyroid carcinoma. Cancer 1996; 77: 2574-80. |
| (75) |
Beierwaltes WH, Rabbani R, Dmuchowski C, Lloyd RV, Eyre
P, Mallette S. An analysis of ablation of thyroid remnants with I-131 in
511 patients from 1947-1984: Experience at University of Michigan. J Nucl
Med 1984; 25: 1287-93. |
| (76) |
Maxon HR, Englaro EE, Thomas SR, et al. Radioiodine-131 therapy for well-differentiated
thyroid cancerﾑa quantitative radiation dosimetric approach: outcome and
validation in 85 patients. J Nucl Med 1992; 33: 1132-36. |
| (77) |
Reynolds JC. Percent 131I uptake and post-therapy 131I
scans: their role in the management of thyroid cancer. Thyroid 1997; 7:
281-84. |
| (78) |
Pujol P, Daures J-P, Nsakala N, Baldet L, Bringer J, Jaffiol C. Degree
of thyrotropin suppression as a prognostic determinant in differentiated
thyroid cancer. J Clin Endocrinol Metab 1996; 81: 4318-23. |
| (79) |
Cooper DS, Specker B, Ho M, et al. Thyrotropin suppression
and disease progression in patients with differentiated thyroid cancer:
results from the National Thyroid Cancer Treatment Cooperative Registry.
Thyroid 1998; 8: 737-44. |
| (80) |
Stall GM, Harris S, Sokoll LJ, Dawson-Hughes B. Accelerated bone loss
in hypothyroid patients overtreated with L-thyroxine. Ann Intern Med 1990;
113: 265-69. |
| (81) |
Bauer DC, Ettinger B, Nevitt MC, Stone KL, for the Study
of Osteoporotic Fractures Research Group. Risk for fracture in women with
low serum levels of thyroid-stimulating hormone. Ann Intern Med 2001; 134:
561-68. |
| (82) |
Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations
as a risk factor for atrial fibrillation in older persons. N Engl J Med
1994; 331: 1249-52. |
| (83) |
Biondi B, Palmieri EA, Fazio S, et al. Endogenous subclinical
hyperthyroidism affects quality of life and cardiac morphology and function
in young and middle aged patients. J Clin Endocrinol Metab 2000; 85: 4701-05. |
| (84) |
Tsang RW, Brierley JD, Simpson WJ, Panzarella T, Gospodarowicz MK, Sutcliffe
SB. The effects of surgery, radioiodine, and external radiation therapy
on the clinical outcome of patients with differentiated thyroid carcinoma.
Cancer 1998; 82: 375-88. |
| (85) |
Farahati J, Reiners C, Stuschke M, et al. Differentiated
thyroid cancer. impact of adjuvant external radiotherapy in patients with
perithyroidal tumor infiltration (stage pT4). Cancer 1996; 77: 172-80. |
| (86) |
Brierley JD, Tsang RW. External-beam radiation therapy in the treatment
of differentiated thyroid cancer. Semin Surg Oncol 1999; 16: 42-49. |
| (87) |
Grigsby PW, Baglan K, Siegel BA. Surveillance of patients
to detect recurrent thyroid carcinoma. Cancer 1999; 85: 945-51. |
| (88) |
Antonelli A, Miccoli P, Fedeghini M, et al. Role of neck ultrasound in
the follow-up of patients operated on for thyroid cancer. Thyroid 1995;
5: 25-28. |
| (89) |
Krishnamurthy S, Bedi DG, Caraway NP. Ultrasound-guided
fineneedle aspiration biopsy of the thyroid bed. Cancer (Cytopathology)
2001; 93: 199-205. |
| (90) |
Franceschi M, Kusic Z, Franceschi D, Lukinac L, Roncevic S. Thyroglobulin
determination, neck ultrasonography and iodine-131 whole-body scintigraphy
in differentiated thyroid carcinoma. J Nucl Med 1996; 37: 446-51. |
| (91) |
Frilling A, Gorges R, Tecklenborg K, Gassmann P, et
al. Value of preoperative diagnostic modalities in patients with recurrent
thyroid carcinoma. Surgery 2000; 128: 1067-74. |
| (92) |
Shiga T, Tsukamoto E, Nakada K. Comparison of (18)F-FDG, (131)I-Na, and
(201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma. J Nucl
Med 2001; 42: 414-19. |
| (93) |
Spencer CA, LoPresti JS, Fatemi S, Nicoloff JT. Detection
of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin
measurement. Thyroid 1999; 9: 435-41. |
| (94) |
Ozata M, Suzuki S, Miyamoto T, Liu RT, Fierro-Renoy F, DeGroot LJ. Serum
thyroglobulin in the follow-up of patients treated with differentiated thyroid
cancer. J Clin Endocrinol Metab 1994; 79: 98-105. |
| (95) |
Schlumberger M, Baudin E. Serum thyroglobulin determination
in the follow-up of patients with differentiated thyroid carcinoma. Eur
J Endocrinol 1998; 138: 249-52. |
| (96) |
Mueller-Gaertner HW, Schneider C. Clinical evaluation of tumor characteristics
predisposing serum thyroglobulin to be undetectable in patients with differentiated
thyroid cancer. Cancer 1988; 61: 976-81. |
| (97) |
Haugen BR, Pacini F, Reiners C, et al. A comparison
of recombinant human thyrotropin and thyroid hormone withdrawal for the
detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999; 84:
3877-85. |
| (98) |
Mariotti S, Barbesino G, Caturegli P, et al. Assay of thyroglobulin in
serum with thyroglobulin autoantibodies: an unobtainable goal? J Clin Endocrinol
Metab 1995; 80: 468-72. |
| (99) |
Spencer CA, Takeuchi M, Kazarosyan M. Current status
and performance goals for thyroglobulin assays. Clin Chem 1996; 42: 164-73. |
| (100) |
Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid
antibodies in the United States population (1988 to 1994): National Health
and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002;
87: 489-99. |
| (101) |
Spencer CA, Takeuchi M, Kazarosyan M, et al. Serum thyroglobulin
autoantibodies: prevalence, influence on serum thyroglobulin measurement,
and prognostic significance in patients with differentiated thyroid carcinoma.
J Clin Endocrinol Metab 1998; 83: 1121-27. |
| (102) |
Ringel MD, Ladenson PW, Levine MA. Molecular diagnosis of residual and
recurrent thyroid cancer by amplification of thyroglobulin messenger ribonucleic
acid in peripheral blood. J Clin Endocrinol Metab 1998; 83: 4435-42. |
| (103) |
Takano T, Miyauchi A, Yoshida H, Hasegawa Y, Kuma K,
Amino N. Quantitative measurement of thyroglobulin mRNA in peripheral blood
of patients after total thyroidectomy. Br J Cancer 2001; 85: 102-06. |
| (104) |
Ladenson PW. Strategies for thyrotropin use to monitor patients with treated
thyroid carcinoma. Thyroid 1999; 9: 429-33. |
| (105) |
Pacini F, Lippi F. Clinical experience with recombinant
human thyroid-stimulating hormone (rhTSH): serum thyroglobulin measurement.
J Endocrinol Invest 1999; 22: 25-29. |
| (106) |
Schlumberger M, Ricard M, Pacini F. Clinical use of recombinant human
TSH in thyroid cancer patients. Eur J Endocrinol 2000; 143: 557-63. |
| (107) |
Mazzaferri EL, Kloos RT. Is diagnostic Iodine-131 scanning
with recombinant human TSH useful in the follow-up of differentiated thyroid
cancer after thyroid ablation? J Clin Endocrinol Metab 2002; 87: 1490-98. |
| (108) |
Sherman SI, Lopez-Penabad L. The use of recombinant human thyrotropin
in the management of thyroid carcinoma and other disorders. In: Meikle AW,
ed. Hormone replacement therapy, 2nd edn. Totowa NJ: Humana Press (in press). |
| (109) |
Niederle B, Roka R, Schemper M, Fritsch A, Weissel M,
Ramach W. Surgical treatment of distant metastases in differentiated thyroid
cancer: indication and results. Surgery 1986; 100: 1088-97. |
| (110) |
Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases
in thyroid carcinoma. J Clin Endocrinol Metab 1997; 82: 3637-42. |
| (111) |
Bernier MO, Leenhardt L, Hoang C, et al. Survival and
therapeutic modalities in patients with bone metastases of differentiated
thyroid carcinomas. J Clin Endocrinol Metab 2001; 86: 1568-73. |
| (112) |
Beierwaltes WH, Nishiyama RH, Thompson NW, Copp JE, Kubo A. Survival time
and ﾒcureﾓ in papillary and follicular thyroid carcinoma with distant metastases:
statistics following University of Michigan therapy. J Nucl Med 1982; 23:
561-68. |
| (113) |
Brierley J, Maxon HR. Radioiodine and external radiation
therapy in the treatment of thyroid cancer. In: Fagin JA, ed. Thyroid cancer.
Boston: Kluwer Academic Publishers, 1998: 285-317. |
| (114) |
Maxon HR, Smith HS. Radioiodine-131 in the diagnosis and treatment of
metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North
Am 1990; 19: 685-718. |
| (115) |
Sisson JC, Giordano TJ, Jamadar DA, et al. 131-I treatment
of micronodular pulmonary metastases from papillary thyroid carcinoma. Cancer
1996; 78: 2184-92. |
| (116) |
Furhang EE, Larson SM, Buranapong P, Humm JL. Thyroid cancer dosimetry
using clearance fitting. J Nucl Med 1999; 40: 131-36. |
| (117) |
Vassilopoulou-Sellin R, Palmer L, Taylor S, Cooksley
CS. Incidence of breast carcinoma in women with thyroid carcinoma. Cancer
1999; 85: 696-705. |
| (118) |
de Vathaire F, Schlumberger M, Delisle MJ, et al. Leukaemias and cancers
following iodine-131 administration for thyroid cancer. Br J Cancer 1997;
75: 734-39. |
| (119) |
Chen AY, Levy L, Goepfert H, Brown BW, Spitz MR, Vassilopoulou-Sellin
R. The development of breast carcinoma in women with thyroid carcinoma.
Cancer 2001; 92: 225-31. |
| (120) |
Pacini F, Gasperi M, Fugazzola L, et al. Testicular function in patients
with differentiated thyroid carcinoma treated with radioiodine. J Nucl Med
1994; 35: 1418-22. |
| (121) |
Vini L, Hyer S, Al-Saadi A, Pratt B, Harmer C. Prognosis
for fertility and ovarian function after treatment with radioiodine for
thyroid cancer. Postgrad Med J 2002; 78: 92-93. |
| (122) |
Ceccarelli C, Bencivelli W, Morciano D, Pinchera A, Pacini F. 131I therapy
for differentiated thyroid cancer leads to an earlier onset of menopause:
results of a retrospective study. J Clin Endocrinol Metab 2001; 86: 3512-15. |
| (123) |
Haugen BR. Management of the patient with progressive
radioiodine non-responsive disease. Semin Surg Oncol 1999; 16: 34-41. |
| (124) |
Vassilopoulou-Sellin R, Goepfert H, Raney B, Schultz PN. Differentiated
thyroid cancer in children and adolescents: clinical outcome and mortality
after long-term follow-up. Head Neck 1998; 20: 549-55. |
| (125) |
Ball DW, Baylin SB, de Bustros AC. Medullary thyroid
carcinoma. In: Braverman LE, Utiger RD, eds. Werner and Ingbars: the thyroid
7th edn. Philadelphia: Lippincott-Raven, 1996: 946-60. |
| (126) |
Horvit PK, Gagel RF. Editorial: The goitrous patient with an elevated
serum calcitoninﾑwhat to do? J Clin Endocrinol Metab 1997; 82: 335-37. |
| (127) |
Hahm JR, Lee MS, Min YK, et al. Routine measurement
of serum calcitonin is useful for early detection of medullary thyroid carcinoma
in patients with nodular thyroid diseases. Thyroid 2001; 11: 73-80. |
| (128) |
Bennedbaek FN, Perrild H, Hegedus L. Diagnosis and treatment of the solitary
thyroid nodule: results of a European survey. Clin Endocrinol (Oxf) 1999;
50: 357-63. |
| (129) |
Redding AH, Levine SN, Fowler MR. Normal preoperative
calcitonin levels do not always exclude medullary thyroid carcinoma in patients
with large palpable thyroid masses. Thyroid 2000; 10: 919-22. |
| (130) |
Gagel RF, Cote GJ. Pathogenesis of medullary thyroid carcinoma. In: Fagin
JA, ed. Thyroid cancer. Boston: Kluwer Academic Publishers, 1998: 85-103. |
| (131) |
Ponder BA, Ponder MA, Coffey R, et al. Risk estimation
and screening in families of patients with medullary thyroid carcinoma.
Lancet 1988; 1: 397-401. |
| (132) |
Niccoli-Sire P, Murat A, Rohmer V, et al. Familial medullary thyroid carcinoma
with noncysteine ret mutations: phenotype-genotype relationship in a large
series of patients. J Clin Endocrinol Metab 2001; 86: 3746-53. |
| (133) |
Hansford JR, Mulligan LM. Multiple endocrine neoplasia
type 2 and RET: from neoplasia to neurogenesis. J Med Genet 2000; 37: 817-27. |
| (134) |
Wohllk N, Cote GJ, Bugalho MMJ, et al. Relevence of RET protooncogene
mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab
1996; 81: 3740-45. |
| (135) |
Freyer G, Ligneau B, Schlumberger M, et al. Quality
of life in patients at risk of medullary thyroid carcinoma and followed
by a comprehensive medical network: trends for future evaluations. Ann Oncol
2001; 12: 1461-65. |
| (136) |
Saad MF, Ordonez NG, Rashid RK, Guido JJ, Hill JCS, Hickey RC, Samaan
NA. Medullary carcinoma of the thyroid. Medicine 1984; 63: 319-42. |
| (137) |
O'Riordain DS, OﾕBrien T, Weaver AL, Gharib H, Hay ID,
Grant CS, van Heerden JA. Medullary thyroid carcinoma in multiple endocrine
neoplasia types 2A and 2B. Surgery 1994; 116: 1017-23. |
| (138) |
Hyer SL, Vini L, AﾕHern R, Harmer C. Medullary thyroid cancer: multivariate
analysis of prognostic factors influencing survival. Eur J Surg Oncol 2000;
26: 686-90. |
| (139) |
Saad MF, Guido JJ, Samaan NA. Radioactive iodine in
the treatment of medullary carcinoma of the thyroid. J Clin Endocrinol Metab
1983; 57: 124-28. |
| (140) |
Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella
T. Medullary thyroid cancer: analyses of survival and prognostic factors
and the role of radiation therapy in local control. Thyroid 1996; 6: 305-10. |
| (141) |
Pacini F, Basolo F, Elisei R, Fugazzola L, Cola A, Pinchera
A. Medullary thyroid cancer. An immunohistochemical and humoral study using
six separate antigens. Am J Clin Pathol 1991; 95: 300-08. |
| (142) |
Fugazzola L, Pinchera A, Luchetti F, et al. Disappearance rate of serum
calcitonin after total thyroidectomy for medullary thyroid carcinoma. Int
J Biol Markers 1994; 9: 21-24. |
| (143) |
Orlandi F, Caraci P, Mussa A, Saggiorato E, Pancani
G, Angeli A. Treatment of medullary thyroid carcinoma: an update. Endocr
Relat Cancer 2001; 8: 135-47. |
| (144) |
Abdelmoumene N, Schlumberger M, Gardet P, et al. Selective venous sampling
catheterisation for localisation of persisting medullary thyroid carcinoma.
Br J Cancer 1994; 69: 1141-44. |
| (145) |
van Heerden JA, Grant CS, Gharib H, Hay ID, Ilstrup
DM. Longterm course of patients with persistent hypercalcitoninemia after
apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg
1990; 212: 395-401. |
| (146) |
Dottorini ME, Assi A, Sironi M, Sangalli G, Spreafico G, Colombo L. Multivariate
analysis of patients with medullary thyroid carcinoma: prognostic significance
and impact on treatment of clinical and pathologic variables. Cancer 1996;
77: 1556-65. |
| (147) |
Scopsi L, Sampietro G, Boracchi P, et al. Multivariate
analysis of prognostic factors in sporadic medullary carcinoma of the thyroid:
a retrospective study of 109 consecutive patients. Cancer 1996; 78: 2173-83. |
| (148) |
Tisell LE, Hansson G, Jansson S, Salander H. Reoperation in the treatment
of asymptomatic metastasizing medullary thyroid carcinoma. Surgery 1986;
99: 60-66. |
| (149) |
Moley JF, Debenedetti MK, Dilley WG, Tisell LE, Wells
SA. Surgical management of patients with persistent or recurrent medullary
thyroid cancer. J Intern Med 1998; 243: 521-26. |
| (150) |
Fleming JB, Lee JE, Bouvet M, et al. Surgical strategy for the treatment
of medullary thyroid carcinoma. Ann Surg 1999; 230: 697-707. |
| (151) |
Wells SA Jr, Skinner MA. Prophylactic thyroidectomy,
based on direct genetic testing, in patients at risk for the multiple endocrine
neoplasia type 2 syndromes. Exp Clin Endocrinol Diabetes 1998; 106: 29-34. |
| (152) |
Chi DD, Moley JF. Medullary thyroid carcinoma: genetic advances, treatment
recommendations, and the approach to the patient with persistent hypercalcitoninemia.
Surg Oncol Clin N Am 1998; 7: 681-706. |
| (153) |
Evans DB, Fleming JB, Lee JE, Cote G, Gagel RF. The
surgical treatment of medullary thyroid carcinoma. Semin Surg Oncol 1999;
16: 50-63. |
| (154) |
Machens A, Gimm O, Hinze R, Hoppner W, Boehm BO, Dralle H. Genotype-phenotype
correlations in hereditary medullary thyroid carcinoma: oncological features
and biochemical properties. J Clin Endocrinol Metab 2001; 86: 1104-09. |
| (155) |
Pierie JP, Muzikansky A, Gaz RD, Faquin WC, Ott MJ.
The effect of surgery and radiotherapy on outcome of anaplastic thyroid
carcinoma. Ann Surg Oncol 2002; 9: 57-64. |
| (156) |
Xu G, Pan J, Martin C, Yeung SC. Angiogenesis inhibition in the in vivo
antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid
carcinoma. J Clin Endocrinol Metab 2001; 86: 1769-77. |
| (157) |
McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid
carcinoma: a 50-year experience at a single institution. Surgery 2001; 130:
1028-34. |
| (158) |
Haigh PI, Ituarte PHG, Wu HS, et al. Completely resected anaplastic thyroid
carcinoma combined with adjuvant chemotherapy and irradiation is associated
with prolonged survival. Cancer 2001; 91: 2335-42. |
| (159) |
Passler C, Scheuba C, Prager G, et al. Anaplastic (undifferentiated)
thyroid carcinoma (ATC). A retrospective analysis. Langenbecks Arch Surg
1999; 384: 284-93. |
| (160) |
Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A national cancer data base
report on 53 856 cases of thyroid carcinoma treated in the US, 1985-1995.
Cancer 1998; 83: 2638-48. |
| (161) |
Moretti F, Farsetti A, Soddu S, et al. p53 re-expression
inhibits proliferation and restores differentiation of human thyroid anaplastic
carcinoma cells. Oncogene 1997; 14: 729-40. |
| (162) |
Sherman SI. Anaplastic carcinoma: clinical aspects. In: Wartofsky L, ed.
Thyroid cancer. a comprehensive guide to clinical management. Totowa, NJ:
Humana Press, 1999: 319-25. |
| (163) |
Takashima S, Morimoto S, Ikezoe J, et al. CT evaluation
of anaplastic thyroid carcinoma. AJR Am J Roentgenol 1990; 154: 1079-85. |
| (164) |
Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. Prognostic factors and
therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg
2001; 25: 617-22. |
| (165) |
Venkatesh YSS, Ordonez NG, Schultz PN, Hickey RC, Goepfert
H, Samaan NA. Anaplastic carcinoma of the thyroid: a clinicopathologic study
of 121 cases. Cancer 1990; 66: 321-30. |
| (166) |
Junor EJ, Paul J, Reed NS. Anaplastic thyroid carcinoma: 91 patients treated
by surgery and radiotherapy. Eur J Surg Oncol 1992; 18: 83-88. |
| (167) |
Kim JH, Leeper RD. Treatment of locally advanced thyroid
carcinoma with combination doxorubicin and radiation therapy. Cancer 1987;
60: 2372-75. |
| (168) |
Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma
with paclitaxel: phase 2 trial using 96-hour infusion. Thyroid 2000; 10:
587-94. |